CDIO Stock Overview
Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Cardio Diagnostics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.69 |
| 52 Week High | US$3.56 |
| 52 Week Low | US$0.17 |
| Beta | 4.97 |
| 1 Month Change | -49.64% |
| 3 Month Change | -66.83% |
| 1 Year Change | -70.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.97% |
Recent News & Updates
Shareholder Returns
| CDIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -20.7% | -0.2% | 2.9% |
| 1Y | -70.3% | -1.0% | 22.2% |
Return vs Industry: CDIO underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: CDIO underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| CDIO volatility | |
|---|---|
| CDIO Average Weekly Movement | 18.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDIO's share price has been volatile over the past 3 months.
Volatility Over Time: CDIO's weekly volatility has decreased from 32% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 8 | Meesha Dogan | cardiodiagnosticsinc.com |
Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.
Cardio Diagnostics Holdings, Inc. Fundamentals Summary
| CDIO fundamental statistics | |
|---|---|
| Market cap | US$14.90m |
| Earnings (TTM) | -US$8.38m |
| Revenue (TTM) | US$17.07k |
873.0x
P/S Ratio-1.8x
P/E RatioIs CDIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDIO income statement (TTM) | |
|---|---|
| Revenue | US$17.07k |
| Cost of Revenue | US$0 |
| Gross Profit | US$17.07k |
| Other Expenses | US$8.39m |
| Earnings | -US$8.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -49,087.81% |
| Debt/Equity Ratio | 12.6% |
How did CDIO perform over the long term?
See historical performance and comparison